Iglesias-Martín Fernando, García-Perla-García Alberto, Yañez-Vico Rosa, Aced-Jiménez Elena, Arjona-Gerveno Esther, González-Padilla Juan-David, Gutierrez-Pérez Jose-Luis, Torres-Lagares Daniel
Facultad de Odontología de Sevilla, C/ Avicena s/n 41009, Sevilla (SPAIN),
Med Oral Patol Oral Cir Bucal. 2014 Nov 1;19(6):e612-5. doi: 10.4317/medoral.19778.
The purpose of this study was to compare the use of amoxicillin (1g) vs amoxicillin and clavulanate (875/125mg) after extraction of retained third molars for prevention of infectious complications.
The study involved 546 patients attending for removal a retained third molar and divided in to two groups: Group 1 - amoxicillin and clavunate (875/125mg) group (n=257) and Group 2 - amoxicillin (1g) group (n=289). All patients were recalled for investigating the possibility of infection, presence of diarrhea and further analgesic intake.
From a total of 546 patients, the frequency of infection was 1.4%, without no statistically differences between the two groups. Group 1 showed statistically higher presence of patients with gastrointestinal complications (p>0.05). In 546 patients, 2.7% of patients reported severe pain that would not relieve with medication.
The results of our study show that the use of amoxicillin (1g) and amoxicillin and clavunate (875/125mg) is similar efficacious in preventing infection after retained third molar extraction but amoxicillin and clavunate (875/125mg) produces more gastrointestinal discomfort.
本研究旨在比较拔除阻生第三磨牙后使用阿莫西林(1g)与阿莫西林克拉维酸钾(875/125mg)预防感染并发症的效果。
该研究纳入了546例前来拔除阻生第三磨牙的患者,分为两组:第1组为阿莫西林克拉维酸钾(875/125mg)组(n = 257),第2组为阿莫西林(1g)组(n = 289)。所有患者均被召回,以调查感染可能性、腹泻情况及进一步的止痛药物服用情况。
在总共546例患者中,感染发生率为1.4%,两组之间无统计学差异。第1组胃肠道并发症患者的发生率在统计学上更高(p>0.05)。在546例患者中,2.7%的患者报告有严重疼痛,药物无法缓解。
我们的研究结果表明,拔除阻生第三磨牙后,使用阿莫西林(1g)和阿莫西林克拉维酸钾(875/125mg)预防感染的效果相似,但阿莫西林克拉维酸钾(875/125mg)会导致更多胃肠道不适。